Clinician’s Brief revisits canine Lyme diagnosis and management: full analysis

Clinician’s Brief is putting canine Lyme borreliosis back in the spotlight with a new podcast episode featuring internal medicine specialist Dr. Jane Sykes, released March 2, 2026. The episode, sponsored by Zoetis, focuses on one of small-animal practice’s recurring gray zones: many dogs in endemic areas test positive for Borrelia burgdorferi exposure, but only a minority develop clinical disease, leaving practitioners to sort out when a positive result is meaningful and when it isn’t. (podcasts.apple.com)

That tension isn’t new. The 2018 ACVIM consensus update, which remains a central reference point, stressed that most seropositive dogs and cats show no clinical signs, while the best-recognized syndrome in dogs, Lyme arthritis, tends to be transient or responsive to oral antibiotics. The more serious concern, Lyme nephritis, is uncommon, poorly understood, and still difficult to predict or definitively link in every case. The statement also noted that the geographic distribution of infected ticks has expanded over time, driven by ecological and land-use factors. (academic.oup.com)

The podcast description suggests Sykes’ discussion tracks closely with those unresolved clinical questions. Clinician’s Brief says the episode covers treatment, vaccination, and the “severe circumstance” of Lyme nephritis, alongside practical guidance on what clinicians should and shouldn’t do with a positive test. That framing is consistent with the publication’s related educational content, including a case review by Dr. Scott Weese that states antimicrobial treatment is likely not warranted for clinically normal, seropositive dogs without proteinuria, while proteinuria should trigger closer evaluation and may warrant doxycycline after other causes are considered. (podcasts.apple.com)

Additional diagnostic context comes from CAPC and Cornell University’s Animal Health Diagnostic Center. CAPC notes that most exposed dogs appear to develop subclinical infection, while clinically affected dogs more often present with fever, shifting-leg lameness, swollen joints, lethargy, or anorexia. Cornell’s Lyme multiplex testing guidance adds that lameness often develops two to five months after infection and describes how antibody profiling can help characterize exposure stage and monitor post-treatment trends. Still, Cornell also points clinicians back to ACVIM for treatment recommendations, underscoring that better diagnostics don’t fully settle the core question of whether a seropositive dog is actually sick. (capcvet.org)

On the epidemiology side, the backdrop is shifting. CAPC’s 2025 Pet Parasite Forecast said Lyme and anaplasmosis continue to expand south and west in the United States, even as the upper Midwest and Northeast remain the highest-risk regions. CAPC called on veterinarians to reinforce year-round prevention, assess risk based on lifestyle and travel, and use testing and vaccination strategically. For practices outside historically endemic regions, that means Lyme conversations may increasingly move from occasional to routine, especially as pet parents travel with dogs or relocate from higher-risk areas. (capcvet.org)

Why it matters: For veterinary professionals, this story is less about a single new finding and more about renewed attention to a persistent diagnostic management problem. The clinical risk is two-sided: undertreating the uncommon dog with genuine Lyme-associated illness, or overtreating the much larger pool of healthy seropositive dogs. ACVIM’s guidance remains notably cautious, including dissent within the panel over whether quantitative antibody results can predict illness, chronic disease, or reinfection. In practical terms, that keeps the emphasis on clinical correlation, urinalysis and UPC monitoring, tick prevention, and careful communication with pet parents who may equate a positive screening test with active disease. (academic.oup.com)

The industry angle is also worth noting. Zoetis’ sponsorship reflects sustained commercial interest in tick prevention and Lyme-related education, while the podcast format suggests publishers see continuing demand for real-world clinical interpretation, not just textbook refreshers. As Lyme risk maps shift and testing remains common in wellness screening panels, veterinarians are likely to keep looking for practical guidance on when to treat, when to monitor, and how to discuss uncertainty without eroding client trust. That’s an inference based on the educational framing of the episode, the sponsor alignment, and the broader expansion in vector-borne disease risk. (podcasts.apple.com)

What to watch: Watch for whether Clinician’s Brief or other veterinary educators translate this discussion into updated protocols, case tools, or stronger recommendations around screening asymptomatic dogs, proteinuria monitoring intervals, vaccination decisions, and the role of newer multiplex assays in everyday practice. (academic.oup.com)